---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034271"
form_type: "8-K"
ticker: "CRBP"
cik: "0001595097"
company_name: "Corbus Pharmaceuticals Holdings, Inc."
filed_at: "2024-03-20T23:59:59+00:00"
generated_at: "2026-06-04T11:38:06.861084+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CEO and CFO adopt Rule 10b5-1 trading plans for up to 159,672 shares

## Summary
- CEO Yuval Cohen plan: sale of up to 117,066 shares beginning June 13, 2024, ending March 15, 2025.
- CFO Sean Moran plan: sale of up to 42,606 shares, same start and termination dates.
- Both plans adopted March 15, 2024, disclosed via 8-K on March 20, 2024.
- Plans intended to satisfy affirmative defense of Rule 10b5-1(c).

## SEC filing metadata
- accession: 0000950170-24-034271
- form_type: 8-K
- ticker: CRBP
- cik: 0001595097
- company_name: Corbus Pharmaceuticals Holdings, Inc.
- filed_at: 2024-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/0000950170-24-034271-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1595097/000095017024034271/crbp-20240320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034271
- JSON: https://secwatch.observer/filing/0000950170-24-034271.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034271.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.